Vascular-specific growth factors and blood vessel formation

By G. Yancopoulos, S. Davis, N. Gale, J. Rudge, S. Wiegand, J. Holash. Nature, 2000

3,861 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/496a44452e5740feb1cea6cfe8f63845462d8100

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

Citations in the corpus

Endothelial cell functions (2003, background): “Following vessel maturation, Ang1 seems to continue to be important in maintaining the quiescence and stability of the mature vasculature (Gale and Yancopoulos, 1999; Yancopoulos et al., 2000).”
Engineering Complex Tissues (2006, neutral): “Arrival of these cells to the immature vessels is hypothesized to eliminate the requirement for VEGF.”
VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. (2002, background): “There are now 20 angiogenesis inhibitors undergoing clinical trials (2), many with encouraging results.”
A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate (2008, background): “Other factors proposed to regulate angiogenesis include: fibroblast growth factors, transforming growth factors a and b, tumor necrosis factor a, interleukin-8, hepatocyte growth factor, angiogenin, and members of the Notch family [52,55,56].”
Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. (2006, background): “Regulation of angiogenesis represents a complex process involving autocrine and paracrine growth factor loops with an interplay between tumor cells and the neovasculature (2).”
Angiogenesis in brain tumours (2007, background): “The angiopoietins constitute a family of endothelial growth factors that are ligands for the tyrosine kinase receptor family Tie (Tie-1 and Tie-2) that is selectively expressed in endothelial cells (for review, see Davis and Yancopoulus, 1999; Yancopoulus et al., 2000).”
Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? (2002, background): “Similarly, the origin of neo-vessels within the expanding tumour tissue has been the subject of intense investigatio”
Adipose Tissue Remodeling: Its Role in Energy Metabolism and Metabolic Disorders (2016, background): “Extracellular matrix (ECM) remodeling, including the degradation of the connective tissue and basement membrane proteins, is necessary during the early stage of angiogenesis (179, 180).”
Angiogenesis: Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma (2003, background): “The vasculogenic-mimicry signalling cascade Researchers have recently learned a great deal about the signal-transduction pathways that regulate blood-vessel formation and stabilization during vasculogenesis and angiogenesi”
Intraventricular Hemorrhage in Premature Infants: Mechanism of Disease (2010, background): “Mouse engineered to be deficient in any of the ligands or receptors develop endothelial tubes, but pericytes fail to associate with endothelial cells, resulting in irregular dilated vasculature with propensity to hemorrhage (42,43).”